EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Cardiac Amyloidosis Therapy: A Systematic Review

Franco Iodice, Marco Di Mauro, Marco Migliaccio, Angela Iannuzzi, Roberta Pacileo, Martina Caiazza, Augusto Esposito

Cardiogenetics · 2021

DOI: 10.3390/cardiogenetics11010002 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cardiogenetics, 2021. Verfasst von Franco Iodice und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart involvement in Cardiac Amyloidosis (CA) results in a worsening of the prognosis in almost all patients with both light-chain (AL) and transthyretin amyloidosis (ATTR). The mainstream CA is a restrictive cardiomyopathy with hypertrophic phenotype at cardiac imaging that clinically leads to heart failure with preserved ejection fraction (HFpEF). An early diagnosis is essential to reduce cardiac damage and to improve the prognosis. Many therapies are available, but most of them have late benefits to cardiac function; for this reason, novel therapies are going to come soon.

Zitieren

APA

Iodice, F., Mauro, M. D., Migliaccio, M., Iannuzzi, A., Pacileo, R., Caiazza, M., & Esposito, A. (2021). Cardiac Amyloidosis Therapy: A Systematic Review. Cardiogenetics. https://doi.org/10.3390/cardiogenetics11010002

Vancouver

Iodice F, Mauro MD, Migliaccio M, Iannuzzi A, Pacileo R, Caiazza M, et al. Cardiac Amyloidosis Therapy: A Systematic Review. Cardiogenetics. 2021. doi:10.3390/cardiogenetics11010002

BibTeX
@article{Iodice2021,
  author = {Iodice, Franco and Mauro, Marco Di and Migliaccio, Marco and Iannuzzi, Angela and Pacileo, Roberta and Caiazza, Martina and Esposito, Augusto},
  title = {Cardiac Amyloidosis Therapy: A Systematic Review},
  journal = {Cardiogenetics},
  year = {2021},
  doi = {10.3390/cardiogenetics11010002}
}
Kostenlos starten →